Leblanc M, Pichette V, Geadah D, Ouimet D
Nephrology and Biochemistry Department, Maisonneuve-Rosemont Hospital and Guy-Bernier Research Center, University of Montreal, Montreal, Canada.
J Ren Nutr. 2000 Oct;10(4):196-201. doi: 10.1053/jren.2000.16327.
To determine the serum status in folate, pyridoxal-5'-phosphate (the active moiety of pyridoxine), cobalamin, and total homocysteine of chronic dialysis patients not routinely supplemented with B-complex vitamins and to evaluate induced intradialytic losses during high-efficiency hemodialysis.
A cross-sectional study.
A university medical center providing tertiary care.
Thirty-six chronic dialysis patients (23 men and 13 women, mean age 57+/-13 years) treated since 3.8+/-2.2 years by hemodialysis and not supplemented with hydrosoluble vitamins.
Thrice-weekly hemodialysis was performed using CT-190G (Baxter, IL) or F-20 (Hospal, St-Leonard, Canada) reused dialyzers with a mean blood flow rate of 371+/-40 mL/min, a dialysate flow rate of 500 mL/min, and a mean session time of 3.7+/-0.4 hours. Prehemodialysis serum vitamin B(12) and homocysteine, and predialysis and postdialysis serum folate, pyridoxal-5'-phosphate, and urea were measured. Blood-side folate and pyridoxal-5'-phosphate clearances were calculated.
Predialysis serum total homocysteine was above normal in all patients, with values ranging from 14.4 to 158.0 micromol/L (mean 40.2+/-29.6 micromol/L, median 33.5 micromol/L). Whereas the majority, 21 patients, had evidence of coronary, cerebrovascular, and/or peripheral vascular diseases, there was no difference in total homocysteine in patients with or without vascular disease (respectively, 40.8+/-37.0 micromol/L v 39.4+/-15.1 micromol/L, P = NS). Predialysis serum concentrations of pyridoxal-5'-phosphate were reduced in 20 patients (56%) and were in the lower normal range for 14 patients. Predialysis and postdialysis serum folate concentrations were 12.4+/-6.1 nmol/L and 8.6 +/- 3.6 nmol/L, whereas predialysis and postdialysis serum pyridoxal-5'-phosphate concentrations were 11.1+/-7.5 nmol/L and 8.0 +/-5.9 nmol/L. Percent reduction ratios were 68.4% +/- 6.6% for urea, 26.3%+/-16.0% for folates, and 27.9%+/-14.2% for pyridoxal-5'-phosphate. Blood-side clearances reached 134.7+/-22.2 mL/min for folates and 54.4+/-38.2 mL/min for pyridoxal-5'-phosphate. There was no significant difference in predialysis serum folate and pyridoxal-5'-phosphate in patients with or without evidence of vascular disease.
This study confirms that: (1) total serum homocysteine levels are very high in chronic hemodialysis patients not supplemented with B-complex vitamins; (2) folate is significantly cleared or lost during high-efficiency hemodialysis; and (3) pyridoxal-5'-phosphate, the active moiety of pyridoxine, is depleted in most chronic hemodialysis patients without supplementation and that high-efficiency hemodialysis contributes to its depletion.
测定未常规补充复合维生素B的慢性透析患者的血清叶酸、磷酸吡哆醛(维生素B6的活性部分)、钴胺素及总同型半胱氨酸水平,并评估高效血液透析过程中这些物质的透析中损失情况。
横断面研究。
一家提供三级医疗服务的大学医学中心。
36例慢性透析患者(23例男性和13例女性,平均年龄57±13岁),接受血液透析治疗3.8±2.2年,未补充水溶性维生素。
每周进行三次血液透析,使用CT - 190G(百特公司,伊利诺伊州)或F - 20(霍斯帕尔公司,加拿大圣莱昂纳德)复用透析器,平均血流速度为371±40 mL/分钟,透析液流速为500 mL/分钟,平均透析时间为3.7±0.4小时。测定透析前血清维生素B12和同型半胱氨酸,以及透析前和透析后血清叶酸、磷酸吡哆醛和尿素水平。计算血液侧叶酸和磷酸吡哆醛清除率。
所有患者透析前血清总同型半胱氨酸均高于正常,范围为14.4至158.0 μmol/L(平均40.2±29.6 μmol/L,中位数33.5 μmol/L)。21例患者有冠状动脉、脑血管和/或外周血管疾病证据,有血管疾病和无血管疾病患者的总同型半胱氨酸水平无差异(分别为40.8±37.0 μmol/L对39.4±15.1 μmol/L,P =无显著性差异)。20例患者(56%)透析前血清磷酸吡哆醛浓度降低,14例患者处于正常低限范围。透析前和透析后血清叶酸浓度分别为12.4±6.1 nmol/L和8.6±3.6 nmol/L,透析前和透析后血清磷酸吡哆醛浓度分别为11.1±7.5 nmol/L和8.0±5.9 nmol/L。尿素的降低百分比为68.4%±6.6%,叶酸为26.3%±16.0%,磷酸吡哆醛为27.9%±14.2%。血液侧叶酸清除率达到134.7±22.2 mL/分钟,磷酸吡哆醛清除率为54.4±38.2 mL/分钟。有或无血管疾病证据的患者透析前血清叶酸和磷酸吡哆醛无显著差异。
本研究证实:(1)未补充复合维生素B的慢性血液透析患者血清总同型半胱氨酸水平非常高;(2)高效血液透析过程中叶酸显著清除或损失;(3)大多数未补充维生素的慢性血液透析患者维生素B6的活性部分磷酸吡哆醛缺乏,且高效血液透析加剧了这种缺乏。